Mosquitoes Developing Resistance to Common Insect Repellents

DEET has been the world's most widely used insect repellent for eight decades. Developed by the U.S. Army in the 1940s and registered for civilian use in 1957, it remains the gold standard recommended by the WHO and the CDC for preventing bites from mosquitoes that transmit malaria, dengue, Zika, and chikungunya [1]. But a growing body of peer-reviewed research suggests that some mosquito populations are becoming less responsive to the compound — through a combination of genetic selection, sensory habituation, and cross-resistance with agricultural insecticides. The implications reach far beyond backyard barbecues: 282 million people contracted malaria in 2024, and an estimated 610,000 died, the vast majority of them children under five in sub-Saharan Africa [2].

The Habituation Discovery

The study that first brought repellent resistance to broad scientific attention was published in 2013 in PLOS ONE by James Logan, Nina Stanczyk, and colleagues at the London School of Hygiene & Tropical Medicine. The team exposed Aedes aegypti mosquitoes — the primary vector for dengue, Zika, and yellow fever — to DEET and then tested them again three hours later. Mosquitoes that had been previously exposed showed measurably decreased repellency. Electrophysiological recordings from their antennae confirmed that olfactory receptor neurons fired less in response to DEET after the initial exposure [3].

The finding suggested something analogous to the way humans stop noticing a persistent smell: the mosquitoes' sensory apparatus was becoming desensitized. Logan's team emphasized that DEET still worked — the mosquitoes were not immune — but the reduced response raised the possibility that under real-world conditions, where mosquitoes encounter repellent-treated humans repeatedly, the compound's protective window could narrow [4].

An earlier study at the University of Florida, published in 2010, had already identified a genetic component. Researchers found that a small proportion of Aedes aegypti individuals were inherently insensitive to DEET — they would approach human odor sources despite the repellent. When these individuals were selectively bred, their offspring inherited the trait, demonstrating that DEET insensitivity could be selected for across generations [5].

The Molecular Mechanisms

The science of how mosquitoes overcome DEET is not settled into a single, clean story. Three distinct mechanisms have been documented:

Olfactory desensitization. In Logan and Stanczyk's work, DEET-exposed mosquitoes showed reduced firing in specific olfactory receptor neurons on the antennae, suggesting a peripheral sensory change rather than a central nervous system adaptation [3].

Genetic insensitivity. The Florida studies identified heritable insensitivity that could spread through a population under selection pressure — meaning that if DEET use removes sensitive mosquitoes from the breeding pool, resistant individuals would become more prevalent over generations [5].

Cross-resistance via insecticide resistance genes. A 2019 study published in Parasites & Vectors by Deletre and colleagues directly tested whether insecticide-resistance mutations in Anopheles gambiae — the main malaria vector in Africa — altered repellent responses. They compared three strains: a susceptible strain (Kisumu), a pyrethroid-resistant strain carrying the kdr (knockdown resistance) mutation, and an organophosphate-resistant strain carrying the ace1 mutation. The results were unexpected: DEET's repellency varied by resistance genotype, with some resistant strains actually showing increased repellency to DEET at high doses, while responses to natural repellents like geraniol and carvacrol were more consistently altered [6].

This third mechanism is significant because it connects repellent efficacy to the broader crisis of insecticide resistance. Mosquito populations across sub-Saharan Africa, South and Southeast Asia, and Latin America have been under intense selection pressure from pyrethroid-treated bed nets and indoor residual spraying for decades. If the same resistance mutations that undermine insecticides also modify responses to repellents — even unpredictably — then the two pillars of personal protection may be eroding in tandem.

The Cytochrome P450 Connection

Insecticide resistance in mosquitoes frequently involves overexpression of cytochrome P450 enzymes — a large family of detoxification proteins that metabolize foreign compounds. Mosquitoes carry over 100 P450 genes, and multiple studies have documented their role in breaking down pyrethroids, the insecticide class used in bed nets [7]. The kdr mutations in voltage-gated sodium channels — such as the L1014F substitution, now documented in Aedes aegypti populations in Myanmar, Mauritania, and across West Africa — confer 10- to 30-fold resistance to DDT and pyrethroids [8][9].

Whether these same pathways metabolize or alter sensitivity to DEET is less clear. One study found evidence that DEET may actually inhibit cytochrome P450 enzymes in some arthropods, complicating the picture further [10]. The research is ongoing, but the concern among entomologists is straightforward: if agricultural and public health insecticide use selects for detoxification enzymes that also process repellent compounds, then resistance to one class could predict cross-resistance to others.

Source: OpenAlex

Data as of Jan 1, 2026CSV

Research output on mosquito repellent resistance has surged — over 11,200 papers have been published since 2011, peaking at 1,476 in 2023, according to OpenAlex data. The growth reflects both genuine scientific concern and the availability of molecular tools to study resistance mechanisms at the genetic level.

The Scale of the Problem

The WHO's 2024 World Malaria Report documented 282 million malaria cases globally, up from 263 million in 2023 and 214 million in 2015 [2]. The African Region accounts for roughly 95% of all cases and deaths, with Nigeria alone responsible for 31.9% of global malaria deaths [2].

Source: WHO World Malaria Report 2024

Data as of Dec 1, 2024CSV

DEET-based products are not the primary malaria prevention tool in endemic Africa — insecticide-treated nets (ITNs) and indoor residual spraying (IRS) are. But repellents serve as a critical supplementary layer, especially for outdoor-biting mosquito species and during hours when people are not under nets. The WHO recommends DEET, picaridin, and IR3535 as effective topical repellents [1]. The global insect repellent market, dominated by DEET formulations, has been valued at several billion dollars annually, with SC Johnson's Off! brand as the leading commercial product [11].

In regions where dengue and Zika are primary concerns — Latin America, Southeast Asia, the Pacific — personal repellent use is often the frontline defense because the Aedes aegypti mosquitoes that transmit these diseases bite during the day, when bed nets provide no protection. Over 3.9 billion people live in dengue-endemic regions across more than 129 countries [12].

The Steelman Case for Caution

Not all researchers are convinced that "repellent resistance" as a field-level phenomenon warrants alarm. Several methodological criticisms deserve attention.

First, the habituation studies by Logan's group exposed mosquitoes to DEET in a laboratory setting and re-tested them after three hours. In practice, humans reapply repellent, and the concentrations used in commercial products (typically 15–30% DEET) may differ substantially from those used in controlled experiments [3].

Second, no large-scale field trial has demonstrated that properly applied DEET-based repellents have lost meaningful protective efficacy against any mosquito species in any region. The resistance documented so far has been measured in terms of reduced avoidance behavior or altered electrophysiology — not in terms of increased human disease transmission in DEET-using populations [13].

Third, the 2019 Parasites & Vectors cross-resistance study found that pyrethroid-resistant Anopheles gambiae strains were actually more repelled by DEET at high doses, not less — a finding that complicates any simple narrative of declining efficacy [6].

Fourth, the heterogeneity in study results across different research groups, mosquito species, DEET concentrations, and exposure protocols makes generalization difficult. As one systematic review noted, differences in "compound concentrations, application dosages, mosquito species, formulations and the assessment method of repellency" can account for much of the variation in reported findings [14].

Mark Fradin, the dermatologist whose landmark 2002 New England Journal of Medicine comparative study helped establish DEET's superiority over alternatives, has argued that DEET remains effective when applied according to label directions [15]. The CDC continues to recommend DEET without qualification [1].

Next-Generation Repellents: How Far Away?

Several research programs are working on compounds that could supplement or replace DEET.

At UC Riverside, entomologist Anandasankar Ray's laboratory has used machine learning to screen over 10 million compounds, identifying natural and synthetic candidates that activate mosquito avoidance pathways. The lab received a $2.5 million NIH grant to develop spatial repellents targeting mosquito olfactory receptors. Some of the natural compounds they identified are already FDA-approved as food flavorings, which could accelerate the regulatory pathway [16].

An international team led by researchers in Israel identified the OR49 olfactory receptor in Aedes aegypti — a receptor specifically tuned to detect borneol, a compound found in camphor trees. When activated, OR49 triggers a hard-wired avoidance response. This discovery suggests a strategy for designing repellents that work at lower concentrations and across multiple mosquito species, by targeting the insect's own sensory architecture rather than relying on a generalized irritant effect [17].

A 2024 study published in PLOS ONE validated a plant-derived repellent blend effective against Aedes aegypti, Anopheles gambiae, and Culex quinquefasciatus in laboratory conditions, demonstrating that natural alternatives can achieve meaningful protection [18].

But the path from laboratory to commercial product is long. DEET's regulatory approval, established safety profile, and manufacturing scale took decades to build. Any new active ingredient would need to pass EPA registration in the United States, meet WHO Pesticide Evaluation Scheme standards for use in malaria-endemic countries, and achieve cost-effective production at scale. Conservative estimates place the timeline for a widely available, WHO-recommended DEET alternative at 8 to 15 years from initial compound identification.

The Cost Equation

The economics of vector control constrain what is possible. Insecticide-treated bed nets remain one of the most cost-effective public health interventions ever measured, at roughly $3,000 to $8,000 per death averted [19]. ITNs have accounted for more than two-thirds of the reduction in malaria cases and deaths since 2000 [19].

But pyrethroid resistance is undermining standard ITNs too. The WHO has recommended next-generation nets combining pyrethroids with a second active ingredient (such as chlorfenapyr or pyriproxyfen) since 2023. These dual-active nets are more effective against resistant mosquitoes but cost more — creating tension in malaria budgets that are already insufficient [20]. In 2024, the WHO updated its IRS guidance to reflect new insecticide options for regions with high pyrethroid resistance [21].

If DEET-based repellents were to lose efficacy in specific regions, the alternatives — spatial repellents, treated clothing, genetically modified mosquitoes — are either less proven, more expensive, or face regulatory and public acceptance barriers. For countries like Nigeria, India, and Brazil, where vector-borne disease exacts the highest toll, any weakening of a cheap, accessible personal protection tool would widen an already large gap between need and resources.

Who Funds the Research?

Repellent resistance research is funded primarily by government agencies and academic institutions. The NIH, the UK Medical Research Council (which funded Logan's habituation studies), and the Bill & Melinda Gates Foundation are among the largest funders of mosquito biology and vector control research globally [16].

SC Johnson, which manufactures Off! and markets DEET-based products worldwide, maintains an insect science research center and states that "DEET can be used with confidence when directions are followed" [22]. The company has not published independent data on repellent resistance. This is not unusual — most insect repellent manufacturers conduct efficacy testing to meet regulatory standards but do not fund or publish basic research on resistance mechanisms. Academic researchers interviewed by media outlets have not alleged corporate suppression of findings, though several have noted that the commercial incentive structure does not encourage manufacturers to investigate whether their flagship products are losing efficacy [4].

The structural dynamic is similar to what has been observed in antimicrobial resistance: the companies that profit from existing compounds have limited incentive to fund research that might undermine confidence in those compounds, while the public health agencies that would benefit from such research are chronically underfunded.

What Comes Next

The evidence so far establishes three things: some mosquitoes can habituate to DEET after short-term exposure; genetic insensitivity to DEET exists in natural populations and is heritable; and insecticide-resistance mutations can modify repellent responses in complex, sometimes contradictory ways. What the evidence does not yet show is that DEET-based repellents have failed at the population level in any real-world setting.

The gap between those two statements defines the current scientific debate. Researchers who study resistance mechanisms argue that waiting for field-level failure before acting is the same mistake that was made with antimicrobial drugs and pyrethroid insecticides — both of which became significantly less effective before the scientific and policy communities responded at scale. Skeptics counter that DEET's mechanism of action is fundamentally different from a drug or insecticide — it repels rather than kills, creating less direct selection pressure for resistance.

Both positions have merit. The prudent course, as described by multiple research groups, is to continue monitoring DEET efficacy in field settings, accelerate development of receptor-targeted alternatives, and avoid reliance on any single compound as the primary barrier between humans and the diseases mosquitoes carry.